Revive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid pharmaceuticals program. More specifically, the company provided an update as it pertains to clinical development of CBD in the treatment of rare diseases.
The company revealed this morning that it has recently entered into a clinical trial agreement with The Trustees of Indiana University to develop and manage a proposed phase 2 clinical study. The study, entitled “Use of Cannabidiol as an adjunct therapy for difficult to treat autoimmune hepatitis,” will focus on the study of the use of CBD against certain liver diseases.
The company is currently in the process of completing protocol and study documents, which will enable the submission of a pre-investigational new drug meeting with the FDA.
The study is the latest development in the firms rare disease cannabinoid product pipeline, with the company in the past having been granted orphan drug designation by the FDA for the use of CBD in the treatment of autoimmune hepatitis, and CBD in the prevention of ischemia and reperfusion injury resulting from solid organ transplantation.
Revive is also in the process of developing novel drug delivery tech for psychedelics and cannabinoids in partnership with the University of Wisconsin-Madison. Such tech includes a hydrogel formulation that is to be used in combination with synthetic CBD, which has been evaluated in a preclinical model that successfully demonstrated a stable formulation with anti-inflammatory activity that compliments CBD. The tech currently shows potential to deliver synthetic and natural cannabinoids in a number of methods, including topical gels, creams, and ointments.
“Over the last year, we have evolved in focusing our clinical development programs in high demand pharmaceutical industries such as psychedelics, cannabinoids and infectious diseases that leverages our expertise in drug repurposing and drug delivery to enhance shareholder value.”
Michael Frank, CEO of Revive
Revive Therapeutics last traded at $0.57 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
